Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Cancer treatment delays caused by the COVID‐19 pandemic may not hinder outcomes
CA: A Cancer Journal for Clinicians  (IF508.702),  Pub Date : 2020-11-10, DOI: 10.3322/caac.21651
Mike Fillon

In response to the coronavirus disease 2019 (COVID-19) pandemic, health care providers and institutions have recommended delaying the treatment of some patients with cancer, especially during peaks of infection incidence, with the intent of reducing patient exposure to the virus and prioritizing health care resources. For patients and clinicians who may be uneasy about delaying cancer treatments during the COVID-19 pandemic, 2 new studies that analyzed data from the National Cancer Data Base (NCDB) have offered some reassurance. Both investigations—a breast cancer study published in the Journal of the American College of Surgeons (2020;231:434-447.e2. doi:10.1016/j. jamco llsurg.2020.06.021) and a prostate cancer study that appeared in JAMA Oncology (2020;6:1630-1632. doi:10.1001/jamao ncol.2020.3545)— concluded that, in many cases, delayed breast surgery and prostate radiotherapy after diagnosis will not lead to worse outcomes. Breast Cancer Study Details